imatinib mesylate has been researched along with EBV Infections in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cochet, H; Hennig, A; Leger, A; Peyrou, J | 1 |
| Chinen, Y; Fujino, T; Horiike, S; Isa, R; Kawaji, Y; Kobayashi, T; Kohno, K; Kuroda, J; Kuwahara-Ota, S; Nakamura, S; Nishiyama, D; Shimura, Y; Tsukamoto, T; Yamaguchi, J | 1 |
| Bräuninger, A; Hansmann, ML; Renné, C | 1 |
| Bordier, V; Decaudin, D; Dewulf, S; Di Santo, JP; Ekue, R; Grandjean, I; Lantz, O; Mathiot, C; Némati, F; Poupon, MF | 1 |
1 review(s) available for imatinib mesylate and EBV Infections
| Article | Year |
|---|---|
[Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].
Topics: Antineoplastic Agents; Autocrine Communication; B-Lymphocytes; Benzamides; Biopsy; Cell Line, Tumor; DNA Mutational Analysis; Epstein-Barr Virus Infections; Hodgkin Disease; Humans; Imatinib Mesylate; Lymph Nodes; Paracrine Communication; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Reed-Sternberg Cells; Signal Transduction; T-Lymphocytes; Transcription, Genetic | 2009 |
3 other study(ies) available for imatinib mesylate and EBV Infections
| Article | Year |
|---|---|
Endomyocardial fibrosis in a context of peritonitis.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Cardiomyopathy, Restrictive; Drug Therapy, Combination; Emergency Service, Hospital; Endomyocardial Fibrosis; Epstein-Barr Virus Infections; Follow-Up Studies; Furosemide; Humans; Image Enhancement; Imatinib Mesylate; Lymphoma; Magnetic Resonance Imaging, Cine; Male; Peritonitis; Thrombolytic Therapy; Tomography, X-Ray Computed; Young Adult | 2017 |
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Lymphoproliferative Disorders; Male; Prednisone; Protein Kinase Inhibitors; Splenomegaly; Tomography, X-Ray Computed; Vincristine | 2019 |
Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Lymphoma, B-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Rituximab; Xenograft Model Antitumor Assays | 2007 |